NEWRON PHARMACEUT. EO-20
Research NEWRON PHARMACEUT. EO-20 (NP5) on Bullrun: market cap EUR 281.92M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNP5
- ExchangeXETRA
- CountryItaly
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 281.92M
- Financial periodFY2025
- RevenueEUR 19.13M
- Revenue growth-62.8%
- Net income-EUR 13.24M
- Free cash flowEUR 32.30M
Valuation Snapshot
latest market cap is EUR 281.92M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 19.13M | -EUR 13.24M | EUR 32.30M | n/a | -0.66 | EUR 12.19M | EUR 38.16M | -EUR 11.14M |
| FY2024 | EUR 51.39M | EUR 15.84M | -EUR 17.63M | n/a | 0.77 | EUR 6.93M | EUR 50.47M | EUR 1.46M |
| FY2023 | EUR 9.06M | -EUR 16.22M | -EUR 10.15M | n/a | -0.91 | EUR 6.34M | EUR 48.42M | -EUR 29.91M |
| FY2022 | EUR 6.09M | -EUR 17.49M | -EUR 11.11M | n/a | -0.98 | EUR 13.42M | EUR 45.66M | -EUR 14.03M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 281.92M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NEWRON PHARMACEUT. EO-20's market cap?
NEWRON PHARMACEUT. EO-20's market capitalization is EUR 281.92M.
What does NEWRON PHARMACEUT. EO-20 do?
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan.